🧬 The investment is part of the German government’s National Strategy for Gene and Cell Therapies.
💉 The centre will develop and produce gene vectors for clinical trials on an industrial scale.
💊 Roche aims to coordinate gene therapy R&D more effectively and bring together gene therapy players.
🌍 Most gene therapy trials are currently taking place in China, the US, and the UK.
Introduction:
Basel-headquartered Roche AG has opened a new €90m gene therapy development centre in Penzberg, Germany. The investment is part of the German government’s “National Strategy for Gene and Cell Therapies” and aims to coordinate research and development more effectively in the field of gene therapy. The centre will primarily focus on producing gene therapy vectors for clinical trials.
- Roche AG has inaugurated a new €90m gene therapy development centre in Penzberg, Germany.
- The investment is part of the German government’s “National Strategy for Gene and Cell Therapies” and aims to coordinate research and development more effectively.
- The centre will primarily produce gene therapy vectors for clinical trials.
- Roche AG is strengthening the value chains in the field of gene therapy in Germany, supplying clinics worldwide.
- The company is also conducting research on new gene and cell therapies for diseases in various fields.
Conclusion:
Roche AG’s new gene therapy development centre in Penzberg, Germany represents a significant investment in the field of gene therapy. The centre will play a key role in producing gene therapy vectors for clinical trials and will help to coordinate research and development efforts in the field. This investment is part of the German government’s broader strategy to advance gene and cell therapies and has the potential to strengthen the gene therapy value chains in Germany. Roche AG’s research in gene and cell therapies is also contributing to advancements in the treatment of diseases in various fields.
